[Analysis of experience in diagnosis and treatment of fetal goiter in patients with Graves' disease complicated with pregnancy]

Zhonghua Yi Xue Za Zhi. 2022 Feb 15;102(6):442-444. doi: 10.3760/cma.j.cn112137-20210724-01651.
[Article in Chinese]

Abstract

This article reported the clinical diagnosis and treatment experience of two cases of fetal goiter in Graves' disease (GD) complicated with pregnancy. Two GD patients took antithyroid drugs regularly during pregnancy and their thyroid functions were well controlled, but the levels of thyrotropin receptor antibody (TRAb) of the two cases were still above the upper limit in the second and third trimester. Two fetuses had fetal goiter in the middle and late stages of pregnancy. After continuously controlling maternal thyroid function and closely monitoring fetal ultrasound, there was no aggravation of the fetal goiter, and the delivery went smoothly. One case had neonatal hyperthyroidism. It is suggested that although the thyroid function was well controlled during pregnancy in patients with GD, the high level of serum TRAb still needs to be alert to the occurrence of fetal goiter, and fetal ultrasound is the most direct non-invasive monitoring method.

本文报道两例Graves病(GD)合并妊娠患者胎儿甲状腺肿的临床诊治经验。两例GD患者孕期规律服用抗甲亢药物,甲状腺功能控制良好,但至孕中晚期促甲状腺激素受体抗体(TRAb)仍高于参考值上限。两例胎儿孕中晚期出现胎儿甲状腺肿大。继续控制孕母甲状腺功能,严密监测胎儿超声,胎儿甲状腺肿均无加重,均顺利分娩,1例存在新生儿甲状腺功能亢进。提示GD合并妊娠患者孕期甲状腺功能虽然控制良好,但是血清TRAb高水平仍需警惕胎儿甲状腺肿的发生,胎儿超声是最直接的无创监测手段。.

Publication types

  • Case Reports

MeSH terms

  • Antithyroid Agents
  • Female
  • Fetus
  • Goiter* / drug therapy
  • Graves Disease* / complications
  • Graves Disease* / diagnosis
  • Graves Disease* / drug therapy
  • Humans
  • Hyperthyroidism*
  • Infant, Newborn
  • Pregnancy
  • Pregnancy Complications*

Substances

  • Antithyroid Agents